Skip to main content
. Author manuscript; available in PMC: 2013 Jan 11.
Published in final edited form as: Diabetologia. 2012 Feb 15;55(5):1446–1457. doi: 10.1007/s00125-012-2477-5

Figure 5.

Figure 5

Dose-related effects of "PKC-ι/λ inhibitor, ATM, on expression of lipogenic (SREBP-1c, FAS, ACC), inflammatory (TNF-α, ILl-1β) and gluconeogenic (PEPCK, G6Pase) enzymes in hepatocytes of non-diabetic humans. Incubation time, 4 hours with or without 1µmol/l insulin. Values are mean ± SEM of 4 or more determinations. Data are from cells used in Fig 3.

HHS Vulnerability Disclosure